Syngene
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Syngene - overview
Established
1993
Location
Bangalore, -, India
Primary Industry
Biotechnology
About
Based in India, Syngene International is a prominent contract research and manufacturing organization that offers integrated scientific services, ranging from drug discovery to development and manufacturing for biopharma and pharmaceutical sectors. Syngene International specializes in contract research and manufacturing services. Founded in 1993 and headquartered in Bangalore, India, the company has evolved through strategic partnerships and collaborations. Under the leadership of CEO Jonathan Hunt, Syngene was acquired in February 2023 by a consortium that included Goldman Sachs Asset Management for INR 11.
912 billion, transitioning from its previous ownership under Biocon Limited. This acquisition marks a significant new phase in its operational strategy, focused on global expansion and enhanced service offerings. Syngene International Limited offers a comprehensive suite of integrated scientific services, including SynVent, which facilitates therapeutic discovery and development across multiple molecule types. Their offerings cover early-stage research through to full-scale manufacturing, tailored to the needs of over 20 leading pharmaceutical and biotech clients.
The company’s facilities, such as the Centre for Advanced Protein Studies in Bangalore, enable innovation in areas with complex regulatory landscapes, serving markets in North America, Europe, and beyond. In the year 2023, Syngene International Limited generated a revenue of INR 397,831,578. 50, with an EBITDA of INR 117,745,886. 70.
The company’s revenue is derived from long-term partnerships with pharmaceutical and biotechnology firms, characterized by bespoke solutions and tailored pricing structures that align with client objectives. With the funding acquired in February 2023, Syngene plans to advance its research capabilities and expand its geographical footprint. The recent acquisition aims to support the launch of new integrated drug discovery products and enhance service delivery in emerging markets. The company is targeting expanded operations in North America and Europe, leveraging its recent capital influx to innovate and scale its offerings by the end of 2024.
Current Investors
GIC, CDPQ, Morgan Stanley Investment Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.syngeneintl.com
Total Amount Raised
Subscriber access only
Syngene - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | Stelis Biopharma’s manufacturing unit | - | ||||||||
| PIPE | Completed | Syngene | - | ||||||||
| Unspecified Exit | Completed | Syngene | - | ||||||||
| IPO | Completed | Syngene | - | ||||||||
| Buyout | Completed | Syngene | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.